Global Opioid Induced Constipation Drugs Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Opioid Induced Constipation Drugs Revenue
• 1.4 Market by Type
  • 1.4.1 Global Opioid Induced Constipation Drugs Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Lubiprostone
  • 1.4.3 Methyl Naltrexone Bromide
  • 1.4.4 Naldemedine
  • 1.4.5 Alvimopan
  • 1.4.6 Other
• 1.5 Market by Application
  • 1.5.1 Global Opioid Induced Constipation Drugs Market Share by Application: 2020 VS 2026
  • 1.5.2 Hospital Pharmacies
  • 1.5.3 Retail Pharmacies
  • 1.5.4 Online Pharmacies
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Global Opioid Induced Constipation Drugs Market Perspective (2015-2026)
• 2.2 Global Opioid Induced Constipation Drugs Growth Trends by Regions
  • 2.2.1 Opioid Induced Constipation Drugs Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Opioid Induced Constipation Drugs Historic Market Share by Regions (2015-2020)
  • 2.2.3 Opioid Induced Constipation Drugs Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Opioid Induced Constipation Drugs Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Opioid Induced Constipation Drugs Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Opioid Induced Constipation Drugs Players by Market Size
  • 3.1.1 Global Top Opioid Induced Constipation Drugs Players by Revenue (2015-2020)
  • 3.1.2 Global Opioid Induced Constipation Drugs Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Opioid Induced Constipation Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Opioid Induced Constipation Drugs Market Concentration Ratio
  • 3.2.1 Global Opioid Induced Constipation Drugs Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Opioid Induced Constipation Drugs Revenue in 2019
• 3.3 Opioid Induced Constipation Drugs Key Players Head office and Area Served
• 3.4 Key Players Opioid Induced Constipation Drugs Product Solution and Service
• 3.5 Date of Enter into Opioid Induced Constipation Drugs Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global Opioid Induced Constipation Drugs Historic Market Size by Type (2015-2020)
• 4.2 Global Opioid Induced Constipation Drugs Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

• 5.1 Global Opioid Induced Constipation Drugs Market Size by Application (2015-2020)
• 5.2 Global Opioid Induced Constipation Drugs Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Opioid Induced Constipation Drugs Market Size (2015-2020)
• 6.2 Opioid Induced Constipation Drugs Key Players in North America (2019-2020)
• 6.3 North America Opioid Induced Constipation Drugs Market Size by Type (2015-2020)
• 6.4 North America Opioid Induced Constipation Drugs Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Opioid Induced Constipation Drugs Market Size (2015-2020)
• 7.2 Opioid Induced Constipation Drugs Key Players in Europe (2019-2020)
• 7.3 Europe Opioid Induced Constipation Drugs Market Size by Type (2015-2020)
• 7.4 Europe Opioid Induced Constipation Drugs Market Size by Application (2015-2020)

8 China

• 8.1 China Opioid Induced Constipation Drugs Market Size (2015-2020)
• 8.2 Opioid Induced Constipation Drugs Key Players in China (2019-2020)
• 8.3 China Opioid Induced Constipation Drugs Market Size by Type (2015-2020)
• 8.4 China Opioid Induced Constipation Drugs Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Opioid Induced Constipation Drugs Market Size (2015-2020)
• 9.2 Opioid Induced Constipation Drugs Key Players in Japan (2019-2020)
• 9.3 Japan Opioid Induced Constipation Drugs Market Size by Type (2015-2020)
• 9.4 Japan Opioid Induced Constipation Drugs Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Opioid Induced Constipation Drugs Market Size (2015-2020)
• 10.2 Opioid Induced Constipation Drugs Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Opioid Induced Constipation Drugs Market Size by Type (2015-2020)
• 10.4 Southeast Asia Opioid Induced Constipation Drugs Market Size by Application (2015-2020)

11 India

• 11.1 India Opioid Induced Constipation Drugs Market Size (2015-2020)
• 11.2 Opioid Induced Constipation Drugs Key Players in India (2019-2020)
• 11.3 India Opioid Induced Constipation Drugs Market Size by Type (2015-2020)
• 11.4 India Opioid Induced Constipation Drugs Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Opioid Induced Constipation Drugs Market Size (2015-2020)
• 12.2 Opioid Induced Constipation Drugs Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Opioid Induced Constipation Drugs Market Size by Type (2015-2020)
• 12.4 Central & South America Opioid Induced Constipation Drugs Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Ironwood Pharmaceuticals Inc
  • 13.1.1 Ironwood Pharmaceuticals Inc Company Details
  • 13.1.2 Ironwood Pharmaceuticals Inc Business Overview
  • 13.1.3 Ironwood Pharmaceuticals Inc Opioid Induced Constipation Drugs Introduction
  • 13.1.4 Ironwood Pharmaceuticals Inc Revenue in Opioid Induced Constipation Drugs Business (2015-2020))
  • 13.1.5 Ironwood Pharmaceuticals Inc Recent Development
• 13.2 Daiichi Sankyo Co Ltd
  • 13.2.1 Daiichi Sankyo Co Ltd Company Details
  • 13.2.2 Daiichi Sankyo Co Ltd Business Overview
  • 13.2.3 Daiichi Sankyo Co Ltd Opioid Induced Constipation Drugs Introduction
  • 13.2.4 Daiichi Sankyo Co Ltd Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
  • 13.2.5 Daiichi Sankyo Co Ltd Recent Development
• 13.3 Pfizer
  • 13.3.1 Pfizer Company Details
  • 13.3.2 Pfizer Business Overview
  • 13.3.3 Pfizer Opioid Induced Constipation Drugs Introduction
  • 13.3.4 Pfizer Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
  • 13.3.5 Pfizer Recent Development
• 13.4 Progenics Pharmaceuticals Inc
  • 13.4.1 Progenics Pharmaceuticals Inc Company Details
  • 13.4.2 Progenics Pharmaceuticals Inc Business Overview
  • 13.4.3 Progenics Pharmaceuticals Inc Opioid Induced Constipation Drugs Introduction
  • 13.4.4 Progenics Pharmaceuticals Inc Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
  • 13.4.5 Progenics Pharmaceuticals Inc Recent Development
• 13.5 Shionogi & Co., Ltd
  • 13.5.1 Shionogi & Co., Ltd Company Details
  • 13.5.2 Shionogi & Co., Ltd Business Overview
  • 13.5.3 Shionogi & Co., Ltd Opioid Induced Constipation Drugs Introduction
  • 13.5.4 Shionogi & Co., Ltd Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
  • 13.5.5 Shionogi & Co., Ltd Recent Development
• 13.6 Allergan Plc
  • 13.6.1 Allergan Plc Company Details
  • 13.6.2 Allergan Plc Business Overview
  • 13.6.3 Allergan Plc Opioid Induced Constipation Drugs Introduction
  • 13.6.4 Allergan Plc Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
  • 13.6.5 Allergan Plc Recent Development
• 13.7 Nektar Therapeutics
  • 13.7.1 Nektar Therapeutics Company Details
  • 13.7.2 Nektar Therapeutics Business Overview
  • 13.7.3 Nektar Therapeutics Opioid Induced Constipation Drugs Introduction
  • 13.7.4 Nektar Therapeutics Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
  • 13.7.5 Nektar Therapeutics Recent Development
• 13.8 Purdue Pharma
  • 13.8.1 Purdue Pharma Company Details
  • 13.8.2 Purdue Pharma Business Overview
  • 13.8.3 Purdue Pharma Opioid Induced Constipation Drugs Introduction
  • 13.8.4 Purdue Pharma Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
  • 13.8.5 Purdue Pharma Recent Development
• 13.9 S.L.A. Pharma AG
  • 13.9.1 S.L.A. Pharma AG Company Details
  • 13.9.2 S.L.A. Pharma AG Business Overview
  • 13.9.3 S.L.A. Pharma AG Opioid Induced Constipation Drugs Introduction
  • 13.9.4 S.L.A. Pharma AG Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
  • 13.9.5 S.L.A. Pharma AG Recent Development
• 13.10 Mundipharma International Limited
  • 13.10.1 Mundipharma International Limited Company Details
  • 13.10.2 Mundipharma International Limited Business Overview
  • 13.10.3 Mundipharma International Limited Opioid Induced Constipation Drugs Introduction
  • 13.10.4 Mundipharma International Limited Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
  • 13.10.5 Mundipharma International Limited Recent Development
• 13.11 Ono Pharmaceutical Co., Ltd
  • 10.11.1 Ono Pharmaceutical Co., Ltd Company Details
  • 10.11.2 Ono Pharmaceutical Co., Ltd Business Overview
  • 10.11.3 Ono Pharmaceutical Co., Ltd Opioid Induced Constipation Drugs Introduction
  • 10.11.4 Ono Pharmaceutical Co., Ltd Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
  • 10.11.5 Ono Pharmaceutical Co., Ltd Recent Development
• 13.12 Takeda Pharmaceutical Company Limited
  • 10.12.1 Takeda Pharmaceutical Company Limited Company Details
  • 10.12.2 Takeda Pharmaceutical Company Limited Business Overview
  • 10.12.3 Takeda Pharmaceutical Company Limited Opioid Induced Constipation Drugs Introduction
  • 10.12.4 Takeda Pharmaceutical Company Limited Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
  • 10.12.5 Takeda Pharmaceutical Company Limited Recent Development
• 13.13 Theravance Biopharma Inc
  • 10.13.1 Theravance Biopharma Inc Company Details
  • 10.13.2 Theravance Biopharma Inc Business Overview
  • 10.13.3 Theravance Biopharma Inc Opioid Induced Constipation Drugs Introduction
  • 10.13.4 Theravance Biopharma Inc Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
  • 10.13.5 Theravance Biopharma Inc Recent Development
• 13.14 Bausch Health
  • 10.14.1 Bausch Health Company Details
  • 10.14.2 Bausch Health Business Overview
  • 10.14.3 Bausch Health Opioid Induced Constipation Drugs Introduction
  • 10.14.4 Bausch Health Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
  • 10.14.5 Bausch Health Recent Development
• 13.15 Cosmo Pharmaceuticals SA
  • 10.15.1 Cosmo Pharmaceuticals SA Company Details
  • 10.15.2 Cosmo Pharmaceuticals SA Business Overview
  • 10.15.3 Cosmo Pharmaceuticals SA Opioid Induced Constipation Drugs Introduction
  • 10.15.4 Cosmo Pharmaceuticals SA Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
  • 10.15.5 Cosmo Pharmaceuticals SA Recent Development
• 13.16 Daewoong Pharmaceutical
  • 10.16.1 Daewoong Pharmaceutical Company Details
  • 10.16.2 Daewoong Pharmaceutical Business Overview
  • 10.16.3 Daewoong Pharmaceutical Opioid Induced Constipation Drugs Introduction
  • 10.16.4 Daewoong Pharmaceutical Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
  • 10.16.5 Daewoong Pharmaceutical Recent Development
• 13.17 C.B. Fleet Company
  • 10.17.1 C.B. Fleet Company Company Details
  • 10.17.2 C.B. Fleet Company Business Overview
  • 10.17.3 C.B. Fleet Company Opioid Induced Constipation Drugs Introduction
  • 10.17.4 C.B. Fleet Company Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
  • 10.17.5 C.B. Fleet Company Recent Development
• 13.18 Sucampo Pharmaceuticals
  • 10.18.1 Sucampo Pharmaceuticals Company Details
  • 10.18.2 Sucampo Pharmaceuticals Business Overview
  • 10.18.3 Sucampo Pharmaceuticals Opioid Induced Constipation Drugs Introduction
  • 10.18.4 Sucampo Pharmaceuticals Revenue in Opioid Induced Constipation Drugs Business (2015-2020)
  • 10.18.5 Sucampo Pharmaceuticals Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer